Diabetes & metabolic syndrome · 2025
Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Shuo, Zhang Yifan, Liu Xuan, Chai Yun, Jia Hongwei, Shu Hua, Fan Yuxin, Ding Li, Liu Ming
Аннотация
AIMS: This study aimed to evaluate the safety and efficacy of finerenone in the treatment of primary aldosteronism (PA).
METHODS: A total of 15 patients with PA were enrolled. The primary endpoint was the proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week (4W) follow-up. Secondary endpoints included changes in serum potassium, 24-h urinary potassium, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Serum creatinine, estimated glomerular filtration rate (eGFR), and hyperkalemia incidence were also assessed during follow-ups.
RESULTS: At baseline, all patients had hypokalemia (serum potassium <3.5 mmol/L). At 4W, 47 % (7/15) of patients achieved normal serum potassium without supplementation. Serum potassium levels significantly increased at the 2W, 4W, and 8W follow-ups compared to baseline (all p < 0.05). SBP significantly decreased at the 4W and 8W follow-ups (all p < 0.05), while DBP showed no significant changes. Increases in serum creatinine and decreases in eGFR were observed, particularly in patients with PA and chronic kidney disease (CKD), although these changes were not statistically significant. No instances of hyperkalemia or unexpected safety concerns were reported.
CONCLUSION: Finerenone effectively increased serum potassium levels and reduced SBP in PA, demonstrating its potential as a promising treatment option.
METHODS: A total of 15 patients with PA were enrolled. The primary endpoint was the proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week (4W) follow-up. Secondary endpoints included changes in serum potassium, 24-h urinary potassium, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Serum creatinine, estimated glomerular filtration rate (eGFR), and hyperkalemia incidence were also assessed during follow-ups.
RESULTS: At baseline, all patients had hypokalemia (serum potassium <3.5 mmol/L). At 4W, 47 % (7/15) of patients achieved normal serum potassium without supplementation. Serum potassium levels significantly increased at the 2W, 4W, and 8W follow-ups compared to baseline (all p < 0.05). SBP significantly decreased at the 4W and 8W follow-ups (all p < 0.05), while DBP showed no significant changes. Increases in serum creatinine and decreases in eGFR were observed, particularly in patients with PA and chronic kidney disease (CKD), although these changes were not statistically significant. No instances of hyperkalemia or unexpected safety concerns were reported.
CONCLUSION: Finerenone effectively increased serum potassium levels and reduced SBP in PA, demonstrating its potential as a promising treatment option.